Stéphane Éderhy
Impact in
-
- Chemotherapy-induced cardiotoxicity and mitigation
- Viral Infections and Immunology Research
- Atrial Fibrillation Management and Outcomes
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
Papers in
-
- Chemotherapy-induced cardiotoxicity and mitigation 20
- Atrial Fibrillation Management and Outcomes 17
- Cardiovascular Function and Risk Factors 14
- Oncology 56
- Cancer Immunotherapy and Biomarkers 31
- Cancer Treatment and Pharmacology 13
- CAR-T cell therapy research 7
- Co-authors
- Franck Thuny (13 shared papers)Jennifer Marchetti Cautela (13 shared papers)Ariel Cohen (29 shared papers)Joe‐Elie Salem (22 shared papers)Franck Boccara (47 shared papers)Joachim Alexandre (10 shared papers)Charles Dolladille (9 shared papers)Javid J. Moslehi (13 shared papers)
- Journals
- Archives of cardiovascular diseases (24 papers)European Heart Journal (15 papers)Journal of the American College of Cardiology (12 papers)International Journal of Cardiology (6 papers)Circulation (6 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Stéphane Éderhy
165 papers receiving 9.9k citations
Stéphane Éderhy's Hit Papers
Peers
Comparison fields: 5 of 124
- Cardiology and Cardiovascular Medicine 4.0k
- Oncology 4.0k
- Internal Medicine 181
- Emergency Medicine 337
- Radiology, Nuclear Medicine and Imaging 850
Countries citing papers authored by Stéphane Éderhy
This map shows the geographic impact of Stéphane Éderhy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Éderhy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Éderhy more than expected).
Fields of papers citing papers by Stéphane Éderhy
This network shows the impact of papers produced by Stéphane Éderhy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Éderhy. The network helps show where Stéphane Éderhy may publish in the future.
Co-authors
The 25 scholars most cited alongside Stéphane Éderhy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 174 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Hit paper breakdown → | 2022 | 1877 |
| 2 | 2023 ESC Guidelines for the management of endocarditis Hit paper breakdown → | 2023 | 782 |
| 3 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper Hit paper breakdown → | 2015 | 728 |
| 4 | Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer Hit paper breakdown → | 2020 | 448 |
| 5 | Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity Hit paper breakdown → | 2017 | 426 |
| 6 | 2019 | 352 | |
| 7 | 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Hit paper breakdown → | 2022 | 333 |
| 8 | 2020 | 279 | |
| 9 | 2009 | 273 | |
| 10 | 2020 | 227 | |
| 11 | 2020 | 220 | |
| 12 | 2013 | 218 | |
| 13 | 2020 | 217 | |
| 14 | 2017 | 194 | |
| 15 | Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis Hit paper breakdown → | 2023 | 163 |
| 16 | 2021 | 152 | |
| 17 | Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial Hit paper breakdown → | 2022 | 134 |
| 18 | Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation Hit paper breakdown → | 2022 | 129 |
| 19 | 2021 | 123 | |
| 20 | 2014 | 114 |
About Stéphane Éderhy
Stéphane Éderhy is a scholar working on Cardiology and Cardiovascular Medicine, Oncology, Emergency Medicine, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 174 papers that have together received 10.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (31 papers), Chemotherapy-induced cardiotoxicity and mitigation (20 papers), Atrial Fibrillation Management and Outcomes (17 papers), Cardiovascular Function and Risk Factors (14 papers), Cancer Treatment and Pharmacology (13 papers), Cardiac Imaging and Diagnostics (13 papers), HIV-related health complications and treatments (10 papers) and CAR-T cell therapy research (7 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (4.0k citations), Oncology (4.0k citations), Internal Medicine (181 citations), Emergency Medicine (337 citations) and Radiology, Nuclear Medicine and Imaging (850 citations). Stéphane Éderhy has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Franck Thuny, Jennifer Marchetti Cautela, Ariel Cohen, Joe‐Elie Salem, Franck Boccara, Joachim Alexandre, Charles Dolladille, Javid J. Moslehi, Ariel Cohen and Catherine Meuleman. Their work appears in journals such as Archives of cardiovascular diseases, European Heart Journal, Journal of the American College of Cardiology, International Journal of Cardiology and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.